Assay of Factor VIII and Other Clotting Factors

Quality in Laboratory Hemostasis and Thrombosis

Volumn , Issue , 2009, Pages 81-89

  Kitchen, S ^a,b,c   Preston, F E ^c,d  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Rutledge Mews   (United Kingdom)

^c WORLD FEDERATION OF HEMOPHILIA   (Canada)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Assay of clotting factors; Assay of clotting factors in plasma and emphasis on factor VIII:C; Chromogenic assay for FVIII:C in plasma; Factor assays in presence of severe deficiency; Lupus anticoagulant (LAC); One stage assay components; One stage assay of factors VIII:C or IX:C; Two stage clotting assay for FVIII:C

Indexed keywords

EID: 77950409837     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303575.ch9     Document Type: Chapter

References (43)

1. World Health Organization Report. Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO/ DIL/LAB/99, 1 Perl. 1999.
2. National Committee for Clinical Laboratory Standards (NCCLS, USA) (1998) Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays, Approved Guideline, 3rd edn. NCCLS: 1998. H21-A3, UH 18, no. 20.
3. Woodhams B, Giradot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-236.
4. Gallus AS, Hirsh J, Cade J. Relevance of pre-operative and post-operative blood tests in post-operative leg vein thrombosis. Lancet 1973; ii: 805-809.
5. Brandt JT. Measurement of factor VIII: A potential risk factor for vascular disease. Arch Pathol Lab Med 1992; 117: 48-51.
6. Preston FE, Kitchen S. Quality control and factor VIII assays. Haemophilia 1998; 4: 651-653.
7. National Committee for Clinical Laboratory Standards (NCCLS, USA). Determination of Factor Coagulant Activities, Approved Guideline. NCCLS: 1997. H48-A.
8. Kitchen S, McCraw A. Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual. Montreal, Canada: World Federation of Hemophilia, 2000.
9. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders: review with guidelines for management. Haemophilia 2004; 10: 1-36.
10. Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring FVIII levels in plasma. Am J Clin Pathol 2003; 120: 34-39.
11. Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF. Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibrinolysis 1998; 9: 623-628.
12. De Maistre E, Wahl D, Perret-Guillaume C, Regnault V, Clarac S, Briquel ME, et al. A chromogenic assay allows reliable measurement of FVIII levels in the presence of strong lupus anticoagulant. Thromb Haemost 1998; 79: 237-238.
13. Armitage J, Ashcraft J, Kim A, Kaplan HS. An approach to factor assays in patients with strong lupus anticoagulant. Clin Appl Thromb Hemost 1995; 1: 125-130.
14. Kitchen S, Cartwright I, Wood TAL, Jennings I, Preston FE. Lipid composition of seven aPTT reagents in relation to heparin sensitivity. Br J Haematol 1999; 106: 801-808.
15. Bowyer AE, Cartwright I, Kitchen S, Makris M. FVIII: C assay discrepancy in type 2N VWD is reagent dependent. J Thromb Haemost 2007; 5: Supplement 2.
16. Arkin CF, Bovill EG, Brandt JT, Rock WA, Triplett DA. Factors affecting the performance of factor VIII coagulant activity assays. Results of proficiency surveys of the College of American Pathologists. Arch Pathol Lab Med 1992; 116: 908-915.
17. Brandt JT, Atkin CF, Bovill EG, Rock WA, Triplett DA. Evaluation of aPTT reagent sensitivity to factor IX and factor IX assay performance. Arch Pathol Lab Med 1990; 114: 135-141.
18. Brandt JT, Triplett DA, Musgrave K, Atkins C, Bovill EG, Ljucas FV, et al. Factor VIII assays. Assessment of variables. Arch Pathol Lab Med 1988; 112: 7-12.
19. Barrowcliffe TW, Tubbs JE, Wong MY. Evaluation of FVIII deficient plasmas. Thromb Haemost 1993; 70: 433-437.
20. Verbruggen B, Giles A, Samis J, Verbeek K, Menisink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001; 86: 1435-1439.
21. Kasper C, Aronson DL, Davignon G, Foster P, Hillman-Wiseman C, Lusher J, et al. Comparison of six commercial reference plasma for FVII, Factor IX and von ASSAY OF CLOTTING FACTORS 89 Willebrand factor, on behalf of the Subcommittee for FVIII and IX of the SSC of the ISTH. Thromb Haemost 1995; 74: 987-989.
22. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendations of the Scientific Subcommittee on FVIII and FIX of the SSC of ISTH. Thromb Haemost 2001; 85: 560.
23. Preston FE, Kitchen S, Jennings I, Woods TAL, Makris M. SSC/ISTH classification of Hemophilia A: can hemophilia center laboratories achieve the new criteria? J Thromb Haemost 2004; 2: 271-274.
24. Yatau R, Dayan I, Baru M. A modified chromogenic assay for the measurement of very low levels of factor VIII activity (FVIII:C). Haemophilia 2006; 12: 253-257.
25. Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs: characterisation of a subgroup of patients with mild haemophilia A and discrepancy in 1-stage and 2-stage assays. Thromb Haemost 1988; 59: 202-206.
26. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between one stage and two stage factor VIII assay methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-848.
27. Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two stage FVIII:C assay demonstrated by a case of mild haemophilia associated with His1954-Leu substitution in the FVIII A3 domain. Br J Haematol 1999; 105: 1123-1126.
28. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A. Mutations in the FVIII gene in seven families with mild haemophilia A. Br J Haematol 1997; 96: 426-427.
29. Rudzi Z, Duncan EM, Casey GJ, Neuman M, Favaloro RJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and familial discrepancy between one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-406.
30. Goodeve AC, Hinks JL, Nesbitt IM, Sampson B, Burgess C, Khair K, et al. Unusual discrepant factor VIII:C assays in haemophilia A patients with Tyr346Cys and Glu- 321Lys FVIII gene mutations. Thromb Haemost 2001; 86(suppl. 1).
31. Mumford AD, Kemball-Cook G, O'Donnell J, Johnson DJD, Manning R, McVey JH, et al. A novel factor VIII variant Tyr346Cys in the acidic a1 domain is associated with an unusual one-stage/two-stage assay discrepancy and delayed thrombin activation. Thromb Haemost 2001; 86 (suppl 1).
32. Mumford AD, Laffan M, O'Donnell J, McVey JH, Johnson JD, Manning RA, et al. A Tyr346Cys in the interdomain acidic region a1 of FVIII in an individual with FVIII:C assay discrepancy. Br J Haematol 2002; 118: 589-594.
33. Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346- Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype: is this mild haemophilia A? Hemophilia 2008; 14: 78-80.
34. Biggs R, Eveling J, Richards G. The assay of antihaemophilic globulin activity. Br J Haematol 1955; 1: 20-34.
35. Denson KWE. Human blood coagulation. In Haemostasis and Thrombosis, Biggs R. (ed.). Blackwells, Oxford, 1976: 682-692.
36. Barrowcliffe TW. Methodology of the two stage assay of FVIII (FVIII:C). Scand J Haematol Suppl 1984; 41: 25-38.
37. Council of Europe. Assay of blood coagulation factor VIII. European Pharmacopoeia, 3rd edn. Strasbourg: 1997: section 2.7.4, 111-114.
38. Barrowcliffe TW. on behalf of the factor VIII and IX subcommittee of SSC of ISTH. Recommendations for the assay of high-purity FVIII concentrates. Thromb Haemost 1993; 70: 876-877.
39. Lundblad RL, Kingdom HS, Mann KG, White GC. Issues with the assay of FVIII activity in plasma and FVIII concentrates. Thromb Haemost 2000; 84: 942-948.
40. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of FVIII activity: general aspects standardisation and recommendations. Semin Thromb Haemost 2002; 28: 247-256.
41. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant FVIII: effect of assay method and standard. Br J Haematol 2001; 113: 533-536.
42. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Colaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using the one-stage clotting assay. J Thromb Haemost 2004; 2: 623-628.
43. Mikaelsson M, Oswaldson U, Sanderg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-650.